As of August 2020, more than 170,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 245,000 patient-years.1
> 6,000 patients in clinical trials and open-label extension
> 167,000 patients with post-marketing experience
As of August 2020, more than 170,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 245,000 patient-years.1
> 6,000 patients in clinical trials and open-label extension
> 167,000 patients with post-marketing experience
References
1. Roche data on file: 31 July 2020, post-marketing experience; 27 March 2020, clinical trials data cut-off